1.
The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer.
Xiong, T, Yang, J, Wang, H, Wu, F, Liu, Y, Xu, R, Lv, Z, Xue, P, Cao, W, Zhang, Y
Molecular biology reports. 2014;(4):2629-34
Abstract
The Lys751Gln polymorphism in the XPD gene have been suggested as a risk factor for bladder cancer, however the results were inconclusive. The aim of the current study is to assess the association by meta-analysis. A total of 15 case-control studies concerning the association between the XPD Lys751Gln polymorphism and bladder cancer risk were included in the meta-analysis. The results suggested that the Lys751Gln polymorphism was not associated with an increased risk of bladder cancer in the dominant model (OR = 1.03, 95 % CI 0.95-1.11, P = 0.53 for Lys/Gln+Gln/Gln vs. Lys/Lys) in overall analysis. In the subgroup analysis by ethnicity, no significant association was found in Caucasians or Asians. Other comparatives suggested a slight significant association between the polymorphism with the risk of bladder cancer in the recessive comparative (OR = 1.14, 95 % CI 1.02-1.29, P = 0.03). The current meta-analysis indicated that the Lys751Gln polymorphism in the XPD gene might be a risk factor for bladder cancer. In the future, more large-scale case-control studies are needed to validate our results.
2.
Letter to the editor: Obvious association between XRCC1 Arg399Gln polymorphism and colorectal cancer in East Asians.
Lu, M, Sun, L, Yang, J, Li, Y
International journal of colorectal disease. 2013;(10):1449-50
3.
Lack of an association between the XRCC1 Arg399Gln polymorphism and gastric cancer based on a meta-analysis.
Liu, BM, Liu, TM, You, BS, You, HY, Yang, J, Li, L, He, YC
Genetics and molecular research : GMR. 2012;(4):3852-60
Abstract
Association between the XRCC1 Arg399Gln polymorphism and susceptibility to gastric cancer has been investigated; overall, the results have been inconclusive. We made a meta-analysis of 13 case-control studies, including 3278 cases and 6243 controls. Crude odds ratios (OR) with 95% confidence intervals (95%CI) were used to assess this possible association. We found no evidence of a significant association between the XRCC1 Arg399Gln polymorphism and gastric cancer risk (in the additive inheritance model, OR = 0.986, 95%CI = 0.831-1.156, in the dominant inheritance model, OR = 1.044, 95%CI = 0.890-1.224 and in the recessive inheritance model, OR = 0.975, 95%CI = 0.894-1.063). We conclude that the XRCC1 Arg399Gln polymorphism is not a risk factor for developing gastric cancer.